Pınar ŞAMLIOĞLU, Gülfem ECE, Sabri ATALAY, Şükran KÖSE

Yoğun bakım birimlerinden izole edilen gram pozitif koklarda daptomisin duyarlılığı

Tepecik Eğitim ve Araştırma Hastanesi’nin Yoğun Bakım Birimlerindeki hastaların çeşitli klinik örneklerinden 16 Nisan-15 Aralık 2010 arasında izole edilen 151 Gram pozitif kok suşunun E-test ile daptomisine, disk difüzyon yöntemi ve Vitek-2 sistemi ile çeşitli antibiyotiklere duyarlılıkları belirlenmiştir. Suşlar metisiline duyarlı ve dirençli stafilokoklar ve enterokoklardan oluşmuştur. Daptomisin, linezolid gibi, suşların tamamına etkili bulunmuş, bu ikisini sadece dört Enterococcus faecium suşunun dirençli olduğu vankomisin ve teikoplanin izlemiştir.

Daptomycin susceptibility in gram positive cocci isolated from intensive care units

The sensitivities of 151 Gram positive cocci isolated from intensive care units of Tepecik Education and Research Hospital between April 16 and December 15, 2010 were determined by E-test for daptomycin and by disk diffusion and Vitek-2 system for other antibiotics. The strains consisted of methicilin sensitive and resistant staphylococci and enterococci. Daptomycin was found to be active on all strains like linezolid, and vancomycin and teicoplanin which were active on the strains except four Enterococcus faecium followed these two antibiotics.

PDF

___

1. Aksoy DY, Unal S. New antimicrobial agents for the treatment of Gram-positive bacterial infec-tions, Clin Microbiol Infect 2008;14(5):411-20. http://dx.doi.org/10.1111/j.1469-0691.2007. 01933.x PMid:18261129
2. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin, Int J Antimicrob Agents 2006;28(5):385-8. http://dx.doi.org/10.1016/j.ijantimicag.2006.07. 017 PMid:17046205
3. Beiras-Fernandez A, Vogt F, Sodian R, Weis F. Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens, Infect Drug Resist 2010;3:95-101. PMid:21694898 PMCid:3108743
4. Bell JM, Turnidge JD, Sader HS, Jones RN. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008), Pathology 2010;42(5):470-3. http://dx.doi.org/10.3109/00313025.2010.493869 PMid:20632825
5. Bozkurt GY, Kutlu H, Arslan A, Memikoğlu O. Yeni bir antibakteriyel ajan: daptomisin, Ankara Üniv Tıp Fak Mec 2010;63(3):85-8.
6. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence, J Antimicrob Chemother 2010;65(6):1126-36. http://dx.doi.org/10.1093/jac/dkq087 PMid:20363805 PMCid:2868529
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 21th Informational Supplement M100-S21, CLSI, Wayne, PA (2011).
8. Cottagnoud P. Daptomycin: a new treatment for insidious infections due to gram-positive pathogens, Swiss Med Wkly 2008;138(7-8):93-9. PMid:18293118
9. Çelikbilek N, Özdem B, Gürelik FC, Güvenman S, Güner HR, Açıkgöz ZC. Metisiline dirençli Staphylococcus aureus izolatlarının vankomisin, teikoplanin, linezolid ve daptomisine in vitro duyarlılıkları, Mikrobiyol Bült 2011;45(3):512-8. PMid:21935784
10. Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008), Braz J Infect Dis 2009;13(2):90-8. PMid:20140350
11. Hawkey PM. Pre-clinical experience with daptomycin, J Antimicrob Chemother 2008;62(3):7-14. http://dx.doi.org/10.1093/jac/dkn367 PMid:18829726
12. Irmak H, Cesur S, Şimşek H. Türkiye’de yoğun bakım ünitelerindeki MRSA suşlarında VISA ve VRSA araştırılması, suşların çeşitli antibiyotikler için MIC değerlerinin belirlenmesi, XXXIII. Türk Mikrobiyoloji Kongresi, Özet Kitabı, Poster S18, s.610, Bodrum (2008).
13. Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use, Expert Opin Pharmacother 2010;11(4):615-25. http://dx.doi.org/10.1517/14656561003598893 PMid:20163272
14. Livermore DM. Has the era of untreatable infections arrived, J Antimicrob Chemother 2009;64(1):29-36. http://dx.doi.org/10.1093/jac/dkp255 PMid:19675016
15. Muder RR, Cunningham C, McCray E et al. Implementation of an industrial systems-engineering approach to reduce the incidence of methicillin-resistant Staphylococcus aureus infection, Infect Control Hosp Epidemiol 2008;29(8):702-8. http://dx.doi.org/10.1086/589981 PMid:18624651
16. Murray BE, Nannini EC. Glycopeptides (vancomycin and teicoplanin), streptogramins (quinupristin-dalfopristin), and lipopeptides (daptomycin), “Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 6. baskı” kitabında s. 425-34, Elsevier Churcill Livingstone, Philadelphia (2005).
17. Öksüz L, Gürler N. Klinik örneklerden izole edilen metisiline dirençli stafilokok suşlarının son yıllarda kullanıma giren antibiyotiklere in-vitro duyarlılık sonuçları, ANKEM Derg 2009;23(2):71-7.
18. Özaras R, Tabak F. Daptomisin, Klimik Derg 2010;23(2):35-8.
19. Piper KE, Steckelberg JM, Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria, J Infect Chemother 2005;11(4):207-9. http://dx.doi.org/10.1007/s10156-005-0395-x PMid:16133715
20. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers 2005, BMC Infect Dis 2007;7:29. http://dx.doi.org/10.1186/1471-2334-7-29 PMid:17442104 PMCid:1865382
21. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections, J Antimicrob Chemother 2005;55(3):283-8. http://dx.doi.org/10.1093/jac/dkh546 PMid:15705644